Trial Profile
Single-center, Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group With Nested Cross-over, Multiple-dose, Up-titration Study of the Effects of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Aug 2014
Price :
$35
*
At a glance
- Drugs Selexipag (Primary)
- Indications Arteriosclerosis obliterans; Pulmonary arterial hypertension; Pulmonary hypertension; Raynaud's disease
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 05 Aug 2014 New trial record